ChiCTR2300068360 版本V1.2 版本创建时间2024/07/25 12:00:36 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300068360 

最近更新日期:

Date of Last Refreshed on:

2023-08-11 19:50:15 

注册时间:

Date of Registration:

2023-02-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

水溶性番茄浓缩物联合红曲干预对血脂异常人群血脂水平的改善作用研究

Public title:

Study on the effect of water-soluble tomato concentrate combined with red yeast rice on blood lipid levels in subjects with dyslipidemia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

水溶性番茄浓缩物联合红曲干预对血脂异常人群血脂水平的改善作用研究

Scientific title:

Study on the effect of water-soluble tomato concentrate combined with red yeast rice on blood lipid levels in subjects with dyslipidemia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

颜睿婷 

研究负责人:

张美琳 

Applicant:

Ruiting Yan 

Study leader:

Meilin Zhang 

申请注册联系人电话:

Applicant telephone:

+86 188 3121 7323

研究负责人电话:

Study leader's
telephone:

+86 138 2176 1583

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

y2353716897@163.com

研究负责人电子邮件:

Study leader's E-mail:

zhangmeilin@tmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市和平区气象台路22号天津医科大学公共卫生学院

研究负责人通讯地址:

天津市和平区气象台路22号天津医科大学公共卫生学院

Applicant address:

School of Public Health, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin, China

Study leader's address:

School of Public Health, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津医科大学

Applicant's institution:

Tianjin Medical University

研究负责人所在单位:

天津医科大学

Affiliation of the Leader:

Tianjin Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科审[2022]第(040)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津医大二院医学伦理委员会

Name of the ethic committee:

The Ethics Committee of the Second Hospital of Tianjin Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-11-02 00:00:00

伦理委员会联系人:

张宝帅

Contact Name of the ethic committee:

Baoshuai Zhang

伦理委员会联系地址:

天津市河西区平江道23号天津医科大学第二医院

Contact Address of the ethic committee:

The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 22 88328108

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津医科大学第二医院

Primary sponsor:

The Second Hospital of Tianjin Medical University

研究实施负责(组长)单位地址:

天津市河西区平江道23号天津医科大学第二医院

Primary sponsor's address:

The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

和平区

Country:

China

Province:

Tianjin

City:

Heping District

单位(医院):

天津医科大学

具体地址:

气象台路22号

Institution
hospital:

Tianjin Medical University

Address:

22 Qixiangtai Road

经费或物资来源:

汤臣倍健营养科学研究基金

Source(s) of funding:

Nutritional science research foundation of BY-HEALTH

研究疾病:

血脂异常  

Target disease:

dyslipidemia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通用随机对照干预研究,探讨水溶性番茄浓缩物和红曲联合干预对血脂异常人群血脂水平的改善作用,为从营养干预改善血脂异常及防治动脉粥样硬化性心血管病的发生、发展提供科学依据。  

Objectives of Study:

By analyzing the design of randomized controlled intervention studies, the combined effects water-soluble tomato concentrate and red yeast rice on improving blood lipid levels in subjects with dyslipidemia are discussed, which provides a scientific basis for improving dyslipidemia and preventing and treating the occurrence and development of atherosclerotic cardiovascular disease from nutritional interventions.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄35-50岁;天津市常住居民; 2.至少1项符合血脂异常诊断标准(2016年中国成人血脂异常防治指南); 3.未经调脂治疗和抗血小板治疗; 4.无严重疾病病史,无凝血障碍或阿司匹林耐受性; 5.自愿参加本实验并签署知情同意书。

Inclusion criteria

1. Aged 35-50 years old, permanent resident in Tianjin; 2. At least 1 compliance with diagnostic criteria for dyslipidemia (2016 Chinese Guidelines for Prevention and Treatment of Adult Dyslipidemia); 3. Have not received the lipomodulation therapy or antiplatelet therapy; 4. Without medical history of serious disease, haemostatic disorders or aspirin tolerance; 5. Voluntarily join the study and sign an informed consent form.

排除标准:

1.患有家族性高脂血症及甲状腺功能异常、肾病综合征等导致的继发性高脂血症;
2.患有糖尿病、冠心病;存在肝肾功能异常,患有风湿免疫系统疾病、结缔组织病、横纹肌溶解症、恶性肿瘤及血液系统疾病;
3.有沟通困难、认知障碍者及精神病患者;
4.处于妊娠或哺乳期;
5.在研究开始前1个月内患有急、慢性感染、发热,有重大手术、外伤史;
6.在研究开始前1个月内服用他汀类药物、抗血小板药物及其它营养补充剂者。

Exclusion criteria:

1. Those with familial hypercholesterolemia or secondary hyperlipidemia caused by abnormal thyroid function and nephrotic syndrome; 2. Those with diabetes mellitus, coronary heart disease; having abnormal liver and kidney function, rheumatic immune system disease, connective tissue disease, rhabdomyolysis, malignant tumor, and hematological system disease; 3. Those with communication difficulties, cognitive impairment, and mental illness; 4. Pregnant or lactating women; 5. Those with acute and chronic infection, fever, and a history of major surgery and trauma within one month prior to the start of the study; 6. Those taking statins, antiplatelet drugs, and other nutritional supplements within one month prior to the start of the study.

研究实施时间:

Study execute time:

From 2022-07-01 00:00:00 To 2024-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-02-24 00:00:00 To 2024-07-31 00:00:00

干预措施:

Interventions:

组别:

水溶性番茄浓缩物干预组

样本量:

40

Group:

water-soluble tomato concentrate

Sample size:

干预措施:

新络素片,口服,6个月

干预措施代码:

Intervention:

oral, 6 months

Intervention code:

组别:

红曲干预组

样本量:

40

Group:

red yeast rice

Sample size:

干预措施:

红曲片,口服,6个月

干预措施代码:

Intervention:

oral, 6 months

Intervention code:

组别:

水溶性番茄浓缩物联合红曲干预组

样本量:

40

Group:

water-soluble tomato concentrate + red yeast rice

Sample size:

干预措施:

新络素红曲片,口服,6个月

干预措施代码:

Intervention:

oral, 6 months

Intervention code:

组别:

对照组

样本量:

40

Group:

control group

Sample size:

干预措施:

安慰剂,口服,6个月

干预措施代码:

Intervention:

placebo, oral, 6 months

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

和平区 

Country:

China

Province:

Tianjin

City:

Heping District

单位(医院):

天津医科大学第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Hospital of Tianjin Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血脂指标

指标类型:

主要指标

Outcome:

lipid profile

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血小板活化功能

指标类型:

次要指标

Outcome:

platelet acativation function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

安全性指标

指标类型:

次要指标

Outcome:

safety index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血小板颗粒释放功能

指标类型:

次要指标

Outcome:

Platelet granule release function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

次要指标

Outcome:

blood glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身体测量指标

指标类型:

次要指标

Outcome:

anthropometry index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 35 years
最大 Max age 50 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

对本研究不知情统计分析人员,采用随机数字法

Randomization Procedure (please state who generates the random number sequence and by what method):

Statistics analyst ignorant to this study uses random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

none

Blinding:

none

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

No

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

天津医科大学

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Tianjin Medical University

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-02-16 10:07:26